AzaSite approval signals $19 million milestone payment

Article

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

AzaSite was shown to be safe and effective in two Phase III trials of more than 1,400 patients in the US and Latin America. The agent was administered twice daily for two days and then once daily for the next three days. The solution was found to offer clinically and statistically significant improvements in clinical resolution of symptoms and bacterial eradication compared with placebo.

AzaSite is formulated with DuraSite, InSite's patented drug delivery vehicle which is designed to enhance retention time of the antibiotic on the surface of the eye.

The approval has triggered a $19 million milestone payment from Inspire Pharmaceuticals, which has commercialization rights for AzaSite in the US and Canada.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.